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Abstract 
Background: In HIV‑1 infected cells, the integrated viral DNA is transcribed by the host cell machinery to generate 
the full length HIV‑1 RNA (FL RNA) that serves as mRNA encoding for the Gag and GagPol precursors. Virion formation 
is orchestrated by Gag, and the current view is that a specific interaction between newly made Gag molecules and FL 
RNA initiates the process. This in turn would cause FL RNA dimerization by the NC domain of Gag (GagNC). However 
the RNA chaperoning activity of unprocessed Gag is low as compared to the mature NC protein. This prompted us to 
search for GagNC co‑factors.
Results: Here we report that RPL7, a major ribosomal protein involved in translation regulation, is a partner of Gag 
via its interaction with the NC domain. This interaction is mediated by the NC zinc fingers and the N‑ and C‑termini of 
RPL7, respectively, but seems independent of RNA binding, Gag oligomerization and its interaction with the plasma 
membrane. Interestingly, RPL7 is shown for the first time to exhibit a potent DNA/RNA chaperone activity higher than 
that of Gag. In addition, Gag and RPL7 can function in concert to drive rapid nucleic acid hybridization.
Conclusions: Our results show that GagNC interacts with the ribosomal protein RPL7 endowed with nucleic acid 
chaperone activity, favoring the notion that RPL7 could be a Gag helper chaperoning factor possibly contributing to 
the start of Gag assembly.
Keywords: HIV, Gag, RPL7, Interaction, Chaperone activity, Nucleocapsid
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
In HIV-1 infected cells, the integrated viral DNA is 
transcribed by the host cell machinery generating the 
full-length viral RNA (also referred to FL RNA), a large 
fraction of which undergoes splicing to give rise to sin-
gle and multi-spliced viral mRNAs [1]. Once exported 
from the nucleus to the cytoplasm, the FL RNA can be 
recruited by active ribosomes to direct synthesis of the 
Gag and GagPol precursors [2]. In infected cells, Gag 
orchestrates virion formation in a process that necessi-
tates two platforms. The first one is thought to be the FL 
RNA acting as a scaffold for Gag oligomerization upon 
binding. The second platform corresponds to the phos-
pholipid bilayer of the plasma membrane in which Gag-
FL RNA complexes are progressively anchored by the 
N-terminus of the Gag matrix (MA) domain [3, 4].
The Gag polyprotein precursor is formed of sev-
eral domains that are the matrix (MA), capsid (CA), 
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nucleocapsid (NC) and p6 as well as the spacer peptides 
p2 and p1 flanking NC [5, 6]. The FL RNA has a long 5′ 
untranslated region (UTR) containing a specific packag-
ing signal composed of four stem-loops that mediate the 
binding of the NC domain of Gag (GagNC) and subse-
quently the formation of a dimeric FL RNA genome 
present in the viral particle [7–15]. This FL RNA dimeri-
zation is driven by the nucleic acid chaperone activity of 
GagNC [16–19] that directs structural rearrangements 
of nucleic acid molecules which rapidly reach their most 
stable structure [20, 21]. However, it was found that 
GagNC chaperone activity was low as compared to the 
mature NCp7 protein present in infectious virions [22–
24]. Along this line, GagNC was also shown to hardly 
anneal primer tRNALys,3 to the Primer Binding Site (PBS), 
thus causing a profound defect in viral DNA synthesis 
[25–27].
This prompted us to look for host chaperoning fac-
tors cooperating with GagNC. Interestingly, several host 
proteins potentially interacting with Gag have been iden-
tified [28–30]. One of these proteins is RPL7 which is 
located at the surface of the large (60S) ribosomal subunit 
[31, 32] (referred in the recent nomenclature to as RPL30 
[33]). RPL7 interacts with RNA [34, 35] and is involved 
in ribosome biogenesis [36] and the regulation of mRNA 
translation [37]. Since several E. coli ribosomal proteins 
behave as RNA chaperones [38, 39], we hypothesized 
that RPL7 may be endowed with chaperone activity 
and may thus cooperate with Gag to direct nucleic acid 
rearrangements.
By means of yeast two-hybrid and co-immunopre-
cipitation experiments, we confirmed the interaction 
between Gag and RPL7 and showed that both the N- 
and C-termini of RPL7 as well as the NC domain of Gag 
are the main determinants for this interaction. Also, the 
Gag–RPL7 interaction seems to be independent of cellu-
lar RNA and on Gag assembly suggesting that Gag mono-
mers or small Gag oligomers could recruit RPL7 during 
the translation process. Using an in  vitro model assay 
[19], RPL7 was found to exhibit a higher nucleic acid 
annealing activity than Gag, and that both proteins can 
act in concert to direct the rapid annealing of comple-
mentary RNAs and DNAs. Taken together, our data sug-
gest that RPL7 may assist GagNC at the very beginning of 
assembly by augmenting its chaperone activity.
Results
HIV‑1 Gag interacts with the cellular ribosomal protein 
RPL7
The interaction between RPL7 and Gag was identified 
by mass spectroscopy [28, 29], sedimentation assay [30] 
and a high throughput two-hybrid screen (R. Benarous, 
personal communication). To confirm this interaction in 
a pairwise two-hybrid analysis, a cDNA coding for the 
full length RPL7 was cloned in fusion with the Gal4p-
AD. As seen in Fig.  1a, diploid yeast cells expressing 
Gal4AD-RPL7 and Gal4BD-Gag had the capacity to grow 
on the selective medium lacking histidine. Controls con-
sisting in the co-expression of either Gal4AD-RPL7 and 
Gal4AD, Gal4AD and Gal4BD-Gag were unable to grow 
in the same conditions indicating that the Gal4 activation 
observed was not due to the transactivation of one of the 
construct alone (Fig. 1a). It is worth noting that interac-
tions were not tested with Gag fused to Gal4AD, due to 
its toxicity for the yeast S. cerevisiae.
To confirm the Gag–RPL7 interaction found by two-
hybrid analysis, we carried out co-immunoprecipitation 
(co-IP) experiments using an anti-CA (anti-p24) antibody 
(Fig. 1b). After HeLa cell transfection of DNA expressing 
Gag, the cell extracts were analyzed for the expression 
of Gag (Fig.  1b, lane 2) and endogenous RPL7 (Fig.  1b, 
lanes 1 and 2) using monoclonal anti-p24 and polyclonal 
anti-RPL7 antibodies, respectively (Input). Then, equal 
quantities of cell extract were incubated with mouse anti-
p24 antibodies and protein A-beads. The immunopuri-
fied material was analyzed by western blot using mouse 
anti-p24 and rabbit anti-RPL7 antibodies (Fig.  1b, IP). 
As shown in Fig.  1b, RPL7 was present together with 
Gag (Fig. 1b, lane 4) but absent from the mock cell lysate 
(Fig. 1b, lane 3) or when immunoprecipitation was per-
formed without anti-p24 (Fig. 1b, lane 5).
To confirm this result, we performed a reverse experi-
ment. To this end, HeLa cells were transfected with a 
plasmid expressing Flag–RPL7 alone or with a plasmid 
expressing Gag-eGFP. HeLa cell lysates were analyzed 
by SDS-PAGE followed by western blot for Flag–RPL7 
and Gag-eGFP expression using anti-Flag (Fig. 1c, lanes 
3 and 4) and anti-eGFP antibodies (Fig.  1c, lanes 2 and 
4), respectively. In parallel experiments, cell lysates were 
incubated with anti-Flag antibody to immunoprecipitate 
RPL7 (Fig. 1c, lanes 7 and 8). In the presence of immu-
noprecipitated RPL7, a specific Gag signal was observed 
with the anti-eGFP antibody (Fig.  1c lane 8). Interest-
ingly, all controls failed to precipitate Gag (Fig. 1c, lanes 
5, 6, 7 and 9) confirming a specific interaction between 
Gag and RPL7.
RPL7 interacts with Gag in HIV infected cells and is 
incorporated into virions
To analyze the Gag–RPL7 interaction in a viral context, 
CEM-SS cells were infected with HIV-1 LAI (CXCR4 
strain). After 4  days, flow cytometry analysis showed 
that 62 % of the cells were infected (data not shown) [40]. 
Equal amounts of lysate from infected or naïve cells were 
analyzed by SDS-PAGE and by western-blotting using an 
anti-p24 antiserum. As seen in Fig.  2a (input), Gag and 
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processed Gag (p41 and p24) were detected in the lysate 
of infected cells (lane 2) but not in that of naïve cells (lane 
1). Meanwhile, these lysates were incubated with anti-
p24 antibody and Gag and processed Gag were immu-
noprecipitated from infected cells lysates (Fig. 2a, lane 5) 
but not from naïve cell lysates (Fig. 2a, lane 4). In addi-
tion, as a control, the infected cell lysate was incubated 
with protein A-beads without anti-p24 antibody and the 
absence of signal in lane 3 (Fig.  2a) indicated that nei-
ther Gag nor RPL7 had nonspecific interactions on the 
beads. Interestingly, incubation of this membrane with 
an antibody directed against RPL7 revealed that endog-
enous RPL7 was co-immunoprecipitated by Gag in such 
infected cells (Fig. 2a, lane 5).
In order to test whether the interaction between Gag 
and RPL7 promotes the incorporation of RPL7 into a 
more relevant physiologically model of virions, HIV-1 
BaL produced in primary cells was purified by a gel exclu-
sion method [40, 41]. RPL7 was detected in these puri-
fied HIV-1 particles (Fig. 2b) while no RPL7 was found in 
the supernatant of naïve primary cells (Fig. 2b, control). 
Taken together, these results show that RPL7 and Gag 
interact in a viral context and that RPL7 can be recruited 
into infectious HIV-1 particles.
To look for the possible role of the Gag–RPL7 interac-
tion in HIV-1 replication, siRNA directed against RPL7 
was transfected and found to induce a large decrease of 
RPL7 protein (data not shown). Nevertheless, other pro-
teins such as actin, RPS14 and nucleolin were impacted 
indicating that silencing of RPL7 has a negative effect on 
the translation machinery [36]. Therefore, due to these 
limitations, we could not evidence any clear impact of the 
Gag–RPL7 interaction on HIV-1 replication.
NC zinc‑fingers are key determinants for the Gag–RPL7 
interaction
In order to further map the GagNC determinants respon-
sible for the interaction with RPL7, co-IP assays were per-
formed using a number of HIV-1 Gag proteins mutated 
in their NC domain (Fig. 3a1). To investigate the role of 
the NC zinc fingers, Gag proteins where either one of the 
two zinc fingers was removed (GagΔZF1 and GagΔZF2) 
were compared to a deletion mutant missing the entire 
NC domain (GagΔNC). To determine the role of the 
basic sequences surrounding the CCHC motifs, both 
zinc fingers were deleted (GagΔZF1ΔZF2) or the 32RKK 
motif was substituted for AAA (GagRAPAAA). Expres-
sion of these Gag constructs was monitored by western 
blotting (Fig.  3a2, input). In parallel experiments, Gag 
and Gag derivatives were immunoprecipitated with anti-
p24 antibody and membranes were immunoblotted with 
anti-p24 or anti-RPL7 antibodies followed by an incuba-
tion with protein A-HRP conjugate (Fig. 3a2, IP). GagNC 
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Fig. 1 HIV‑1 Gag interacts with human ribosomal protein RPL7. a 
Photograph of a plate with diploid yeast cells expressing Gal4BD 
alone or fused to either NCp7, Gag or GagΔNC (pGBKT7 construct) 
and Gal4AD alone or in fusion to RPL7 (pActII construct). Yeasts were 
plated on minimal media lacking histidine, leucine and tryptophan 
and incubated during 6 days at 30 °C. Growth in the absence of 
histidine reveals the interaction between the hybrid proteins. Note 
that NCp7 and Gag interact with RPL7 while marginal interaction was 
observed between Gag∆NC and RPL7. b Gag co‑precipitates with 
endogenous RPL7. Lysates from HeLa cells transfected with pcDNA 
(lanes 1 and 3) or a plasmid expressing Gag (lanes 2 and 4) were sub‑
jected to IP (1 mg of total protein) using anti‑p24 antibody. 20 µg of 
total protein (input) and resuspended beads were analyzed western 
blot with anti‑p24, anti‑RPL7 and anti‑GAPDH antibodies revealed 
by protein A‑HRP. RPL7 signal was observed in lane 4 showing that 
RPL7 was captured by Gag. In contrast, no RPL7 signal was observed 
in the pcDNA tranfected cells (lane 3) or in the assay where the beads 
were incubated in absence of anti‑p24 antibody (lane 5). c Flag–RPL7 
co‑precipitates Gag‑eGFP. HeLa cells were transfected with pcDNA 
(lanes 1 and 5), Gag‑eGFP (lanes 2 and 6), Flag–RPL7 (lanes 3 and 7) or 
co‑transfected with Flag–RPL7 and Gag‑eGFP (lanes 4, 8 and 9). IP was 
performed with 1.5 mg of total protein with a mouse anti‑Flag anti‑
body. 20 µg of input (lanes 1–4) and IPs (lanes 5–8) were resolved by 
10 % SDS‑PAGE and analyzed by immunostaining using an antibody 
directed against Flag to detect RPL7, eGFP to detect Gag, and GAPDH 
as a loading control. RPL7 is able to co‑immunoprecipitate Gag‑eGFP 
in HeLa cells (lane 8). No unspecific binding between Flag–RPL7 and 
beads was observed in the control without anti‑flag antibody (lane 9)
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mutants were immunoprecipitated (Fig.  3a2, lanes 1–6) 
with a higher efficiency as compared to the wild-type 
Gag protein (Fig. 3a2, lane 1), probably as a result of the 
masking of Gag epitopes due to the stronger ability of 
wild-type Gag to oligomerize, as compared to the Gag 
mutants [42–44]. These membranes were subsequently 
immunoblotted with the anti-RPL7 antibody, showing 
that endogenous RPL7 was captured by Gag, GagΔZF1, 
GagΔZF2 and GagRAPAAA (Fig.  3a2, lanes 1, 3, 4 and 
5, respectively) at similar levels. In sharp contrast, RPL7 
was poorly immunoprecipitated by Gag lacking either the 
entire NC domain or both zinc fingers (Fig. 3a2, lanes 2 
and 6, respectively). Taken together, these results indicate 
that the ZFs but not the flanking basic sequences are key 
determinants for the interaction with RPL7.
Finally, a co-IP assay was carried out on cells express-
ing eGFP and NCp7-eGFP using an anti-GFP serum 
(Fig. 3b, input, lane 2 and 3). Endogenous RPL7 was co-
eluted with NCp7-eGFP (Fig. 3b, lane 6) but not with the 
eGFP control (Fig. 3b, lane 5), thus confirming the two-
hybrid screen (Fig. 1a). Taken together, these results indi-
cate that NC, either in the form of GagNC or as mature 
NCp7, interacts with endogenous RPL7.
Gag–RPL7 interaction is RNA independent
The NC domain of Gag and RPL7 are RNA binding pro-
teins [34, 35, 45]. To determine the importance of RNA 
for the Gag–RPL7 interaction, lysates of cell express-
ing Gag and endogenous RPL7 were treated with RNase 
prior to IP with an anti-p24 antiserum. After RNase 
treatment, Gag was immunoprecipitated and detected 
by anti-p24 antibody (Fig.  3c, upper membrane). Then 
membranes were incubated with anti-RPL7 antibody 
and the endogenous protein was detected (Fig.  3c, 
lower membrane). Interestingly, the detection of RPL7 
in the two samples shows that the RPL7 remains asso-
ciated with Gag upon RNase treatment indicating that 
RNA may not be involved in the Gag–RPL7 interaction. 
Intriguingly, in a reproducible manner, the RPL7 signal 
was found to increase upon RNase-treatment (Fig.  3c) 
despite equal quantity of Gag immunoprecipitated on 
beads. To control the RNAse activity, RNA extraction by 
phenol–chloroform was performed on an aliquot of cell 
lysate containing RNAse. As seen in Additional file  1: 
Fig. S1, no RNA was detected in presence of RNAse 
while a smear of RNA was obtained without treatment. 
In addition, similar experiments were carried out with 
cells expressing NCp7-eGFP. As indicated (Fig.  3b, lane 
7) NCp7-eGFP was able to precipitate endogenous RPL7 
in presence of RNAse. Taken together, these results show 
that the interaction between Gag and RPL7 is probably 
not relying on a RNA template.
The Gag–RPL7 interaction is independent 
from Gag‑membrane interaction or Gag–Gag 
oligomerization
During assembly, newly made Gag molecules are pro-
gressively anchored onto the internal leaflet of the plasma 
membrane via the Matrix N-terminus and its myristate 
group at position 2. The G2A mutation impairs Gag 
membrane binding [46, 47], causing its accumulation in 
the cytoplasm [48, 49]. The absence of Gag myristoylation 
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Fig. 2 Interaction of HIV‑1 Gag and RPL7 in infected cells and virion incorporation of RPL7. a Interaction of HIV‑1 Gag and RPL7 in infected cell. Cell 
lysates of naïve CEM‑SS (Lanes 1 and 4) or of HIV‑1 LAI infected CEM‑SS (lanes 2 and 4) were subjected to IPs 3 days post infection using anti‑p24 
antibody and protein A beads. The IP was followed by western blotting with anti‑p24 and anti‑RPL7 antibodies revealed by protein A‑HRP and anti‑
rabbit HRP conjugate, respectively. Additionally, the total amount of protein loaded on the gel was controlled by anti‑GAPDH antibody (input, lanes 
1 and 2). A bead control using the infected cell lysate in the absence of p24 antibody was also performed (lane 3), confirming the specific binding 
of Gag and its processed forms (p24, p41, p55). b RPL7 is incorporated into HIV‑1 particles. HIV‑1 BaL virus stock produced on PHA‑activated PBMC 
were purified and concentrated before been analyzed by western blotting using anti‑p24 and anti‑RPL7 antibodies. The control represents the puri‑
fied supernatant from mock‑infected PBMC using the same purification protocol
Page 5 of 14Mekdad et al. Retrovirology  (2016) 13:54 
Input IP anti-p24
1 2 3 4 65
WB anti-p24
WB anti-GAPDH
WB anti-RPL7
a1
1gaG
2CN∆gaG
5AAAPARgaG
31FZ∆gaG
MAp17 CAp24 p1 p6p2
MAp17 CAp24 p1 p6p2
MAp17 CAp24 p1 p6p2
MAp17 CAp24 p1 p6p2
MAp17 CAp24 p1 p6p2
62FZ1FZ∆gaG MAp17 CAp24 p1 p6p2
42FZ∆gaG
a2
c
IP  anti-p24
RNAse A - +
WB anti-p24
WB anti-RPL7
Gag
WB anti-eGFP
WB anti-RPL7
Input IP anti-eGFP
WB anti-GAPDH
eGFP
NCp7-eGFP
RPL7
63 41 2 5 7 8b
RNAse A
Number of each construct 1 2 3 4 65 7
NCp7-eGFP
eGFP -
-
-
-
-
-
+
-
-
+
-
-
-
+
-
-
+
-
-
+
-
-
+
+
Gag and 
Gag derivatives
RPL7
RPL7
Fig. 3 The NC domain of Gag mediates Gag–RPL7 interaction in an RNA independent manner. a1 Gag and truncated Gag constructs used in the 
present study. Numbers on the right correspond to numbers of lanes of a2. a2 The NC domain of Gag is important for the RPL7–Gag interaction. 
HeLa cells were not transfected (NT) or transfected with pcDNA or plasmids encoding either Gag (construct 1), Gag∆NC (construct 2), Gag∆ZF1 
(construct 3), Gag∆ZF2 (construct 4), GagRAPAAA (construct 5) and Gag∆ZF1ZF2 (construct 6). IP was performed with 1 mg of total protein and 
with an anti‑p24 antibody. 20 µg of cell lysate (input) or IP resuspended samples were resolved by 10 % SDS‑PAGE and analyzed by immunoblotting 
using antibodies against p24, RPL7 and GAPDH revealed by protein A‑HRP, anti‑rabbit HRP conjugate or anti‑mouse HRP conjugate, respectively. 
Nonspecific binding was not observed in the control without antibody (lane 7). b NCp7‑RPL7 interaction is RNA independent. Cell lysate from HeLa 
cells transfected with empty pcDNA (lanes 1, 4) or plasmids coding for eGFP (lanes 2, 5) or NCp7‑eGFP (lanes 3, 6). Cell lysates were immunoprecipi‑
tated with an anti‑eGFP and the immunoprecipitated material was examined by western blot using anti‑eGFP, RPL7 and GAPDH antibodies. Lane 
7 cell lysates expressing NCp7‑eGFP were treated with RNase before immunoprecipitation. Lane 8 cell lysate expressing NCp7‑eGFP was incubated 
with protein A beads but without anti‑eGFP antibody. c Gag–RPL7 interaction is RNA independent. Cell lysate from HeLa cells transfected with 
Gag was treated with RNase. After RNase treatment, cell lysate was immunoprecipitated with anti‑p24 antibody, and the immunoprecipitate was 
analysed by western blot using anti‑p24 and anti‑RPL7 antibodies
Page 6 of 14Mekdad et al. Retrovirology  (2016) 13:54 
had no effect on the ability of Gag to immunoprecipitate 
RPL7 (Fig.  4, lane 9) indicating that Gag–RPL7 interac-
tion does not require membrane association. Taking 
into account that G2A mutation also impairs, at least 
in part, Gag–Gag interaction [43, 44] this result indi-
cates that Gag multimerization is probably not essential 
for the Gag–RPL7 interaction. In agreement with this 
conclusion, a Gag mutated in the capsid (M369A) with 
a severe defect in Pr55Gag assembly [42, 44, 50–52] was 
found to immunoprecipitate RPL7 as efficiently as the 
wild-type Gag (Fig. 4, lane 10). Taken together these data 
show that the Gag–RPL7 interaction does not rely on the 
association of Gag with the plasma membrane and its 
oligomerization.
Major RPL7 determinants for the interaction with HIV‑1 
Gag
To map the RPL7 determinants involved in Gag inter-
action, we used a panel of deletion mutants (Fig.  5a). 
The design of these mutants is based on the previously 
reported roles of the different domains of RPL7. Con-
structs C, E and G contain RPL7 C-terminus which 
interacts with the plasma membrane (PM) and RNA [34, 
53]. Constructs B, E and F contain the RPL7 N-terminus 
which also interacts with nucleic acids and possesses a 
leucine zipper that promotes RPL7 self-oligomerization 
[54]. To discriminate the importance of each termi-
nus with the central region of RPL7, a construct was 
designed harboring only the central domain (RPL7 D) 
and compared with a construct containing both the N- 
and C- termini (RPL7 E). Also, to underline the impor-
tance of RPL7 3-D structure [32, 55], a partial deletion 
in the central domain of RPL7 C was designed (RPL7 
G). The immunoprecipitation of the RPL7 mutants was 
tested using anti-eGFP antibodies on HeLa cells express-
ing Gag-eGFP. Each lysate tested had an equal level of 
Gag-eGFP expression (Fig.  5b, input). Moreover, RPL7 
(Fig.  5b, input, lanes 2 and 4) and RPL7 B, C, E and G 
(Fig.  5b, input, lanes 5, 6, 8 and 10) were expressed at 
a similar level except for RPL7 D and F (Fig.  5b, input, 
lanes 7 and 9). As shown in Fig. 5b (IP), RPL7 B, E and F 
(lanes 5, 8 and 9) containing the N-terminus and RPL7 C 
containing the C-terminus (lane 6) were immunoprecipi-
tated by Gag and visualized by anti-Flag (IP).This result 
points to the importance of both the N- and C-termini 
of RPL7 for the interaction with Gag. Indeed, despite the 
low expression level when both N- and C- termini were 
removed (RPL7 D, input, lane 7), this construct was not 
immunoprecipated by Gag (IP, lane 7) suggesting that 
the central globular domain of RPL7 is dispensable for 
Gag interaction. In addition, there are likely other RPL7 
domains involved in the interaction between RPL7 and 
Gag since deletion of the 155–168 sequence of construct 
C (RPL7 G) prevented Gag-mediated co-precipitation 
of RPL7 (Fig. 5b, IP, lane 10). However, this highly basic 
domain is located at the surface of the protein in a turn 
linking two α helices and the absence of interaction could 
result from a global change in the protein structure [32, 
55]. Thus, our data show that the two terminal domains 
of RPL7 (residues 1–54 and 198–248) are required for 
Gag–RPL7 interaction.
RPL7, Gag and Gag–RPL7 mixture have DNA/RNA 
chaperone activity
Next, we investigated the nucleic acid annealing activity 
of RPL7, Gag, and RPL7 and Gag together using puri-
fied proteins (Additional file  2: Fig. S2). The annealing 
activity of RPL7 was examined using an in  vitro assay 
based on the annealing of dTAR, the DNA equivalent 
of the HIV-1 transactivation responsive element (TAR) 
with its complementary sequence cTAR DNA labeled 
by Rh6G and Dabcyl at its 5′ and 3′ ends, respectively 
[19, 56–60]. As shown in Fig.  6a (panel I, black curve), 
the emission of 10 nM of free labelled cTAR is low as a 
result of the close proximity of cTAR ends inducing a 
strong fluorescence quenching of Rh6G by the Dabcyl 
group [61]. Next, addition of 1 equivalent of RPL7 to this 
solution did not induced any increase in Rh6G fluores-
cence emission (Fig. 6a, panel I, dotted line), suggesting 
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Fig. 4 The Gag–RPL7 interaction is independent on Gag myristoyla‑
tion and oligomerization. Lysates from HeLa cells transfected with 
pcDNA (lanes 2, 7) or plasmids coding for Gag (lanes 3, 8 and 11), 
Gag‑G2A (lanes 4, 9) and Gag‑M369A (lanes 5, 10). Control: lysate from 
non‑transfected HeLa cells (lanes 1, 6). The lysates were subjected to 
IP (1 mg of total protein) using anti‑p24 antibody followed by west‑
ern blot where 20 µg of total protein (input) and resuspended beads 
were analyzed with anti‑p24, anti‑RPL7 and anti‑GAPDH antibodies 
revealed by protein A‑HRP, anti‑rabbit HRP conjugate or anti‑mouse 
HRP conjugate, respectively. All Gag proteins (WT or mutants) interact 
with endogenous RPL7 (lanes 8–10). Neither Gag nor RPL7 bands 
were observed in non‑transfected cells (lane 6), in pcDNA transfected 
cells (lane 7), or in the control of beads without anti‑p24 (lane 11). X 
Heavy chain of anti‑p24 used to IP Gag and Gag derivatives
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that, in contrast to NCp7 [62, 63], RPL7 is unable to melt 
the lower half of the cTAR stem (panel I, insert). Addi-
tion of a mixture of 100 nM of RPL7 and 100 nM of non-
labeled dTAR to obtain pseudo-first order conditions 
induced a sevenfold increase of Rh6G emission (Fig. 6a, 
panel I, dashed line and Table  1). This increase results 
from the annealing of doubly labelled cTAR to dTAR 
and can be monitored in real time (Fig.  6b, red curve). 
The plateau, which corresponds to the total annealing of 
cTAR and dTAR into an extended duplex (ED) (Fig. 6b, 
insert), was completed in ~2000 s, while more than one 
day was needed in the absence of protein [57], indicating 
that RPL7 is endowed with a potent nucleic acid anneal-
ing activity. This kinetic curve was fitted by using a bi-
exponential function with kobs1 = 10.6(±0.8) × 10−3 s−1 
and kobs2 =  10.2(±0.3) ×  10−4  s−1 (Table  1). To further 
confirm the nucleic acid annealing activity of RPL7, 
dTAR was substituted for TAR RNA. Full annealing of 
cTAR with 1  µM of TAR was obtained in 3500  s with 
kobs1 = 44(±1) × 10−4 s−1 and kobs2 = 39(±2) × 10−5 s−1 
(Fig. 6c, red curve, Table 2), indicating that RPL7 is also 
able to promote annealing with RNA sequences, but less 
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Fig. 5 Mapping of the Gag interaction domains in RPL7. a Scheme of Flag–RPL7 and its mutants: Flag–RPL7 mutants used in the present study 
are presented with a grey rectangle (RPL7 sequence conserved in the constructs) and with a black line (RPL7 sequence deleted in the constructs). 
Letters correspond to each construct and are used in b. On the right, (+) and (−) report the ability of each construct to be co‑precipitated with 
Gag‑eGFP. b Identification of Flag–RPL7 interaction with Gag‑eGFP by immunoprecipitation experiments. HeLa cells were either not transfected 
(lane 1), or co‑transfected with plasmids expressing eGFP and Flag–RPL7 (a, lane 2), Gag‑eGFP alone (lane 3) or Gag‑eGFP combined with Flag–RPL7 
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residual signal of the secondary anti‑mouse interacting with primary anti‑Flag antibody
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efficiently than the corresponding DNA sequences. A 
similar difference in efficiency as a function of the nature 
of the nucleic acid was also reported for NCp7 and was 
attributed to the higher stability of the RNA as compared 
to the DNA sequences [57]. In conclusion, our data indi-
cate that, by analogy to ribosomal proteins L1 and L19 
from E. coli [38], the human RPL7 is endowed with effi-
cient nucleic acid annealing activities.
Next, we investigated the annealing activity of Gag in 
similar conditions. Addition of 10 nM of Gag to 10 nM 
of doubly labelled cTAR induced a limited increase in 
the emission of Rh6G (Fig. 6a, panel II, dotted line), sug-
gesting that Gag has marginal destabilization activity in 
these conditions. Addition of 100 nM of Gag and 100 nM 
of non-labeled dTAR resulted in a large increase in Rh6G 
emission (Fig.  6a, panel II, dashed curve) that can be 
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Fig. 6 DNA and RNA annealing activity of RPL7. a Emission spectra of Rh6G‑cTAR‑Dabcyl. (I) Emission spectra of 10 nM Rh6G‑cTAR‑Dabcyl (black 
line) with 10 nM RPL7 (dotted line) or with 100 nM dTAR + 100 nM RPL7 after completion of the annealing reaction (dashed line). Inset scheme of 
closed doubly labelled cTAR: red star corresponds to Rh6G and black circle of Dabcyl. (II) Emission spectra of 10 nM Rh6G‑cTAR‑Dabcyl (black line) 
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traces for the reaction of 10 nM doubly labeled cTAR with 100 nM non‑labeled dTAR in the presence of 100 nM of RPL7 (red trace) or 100 nM of 
Gag (blue trace) or 100 nM of a mixture containing 50 nM of Gag and 50 nM of RPL7 (green trace). Each curve corresponds to a single assay but is 
representative of four independent measurements. All assays were fitted by a bi‑exponential equation and the values of the kinetic rate constants 
were reported in Table 1. Inset describes the scheme of cTAR‑dTAR annealing. Formation of the duplex increases the distance between Rh6G and 
Dabcyl and thus restores Rh6G emission. c Real time monitoring of cTAR‑TAR annealing. Kinetic traces for the reaction of 10 nM doubly labeled cTAR 
with 1 µM of non‑labeled TAR in the presence of 1 µM of RPL7 (red trace) or 1 µM of Gag (blue trace) or 1 µM of a mixture containing 500 nM of Gag 
and 500 nM of RPL7 (green trace). Each curve corresponds to a single assay but is representative of four independent measurements. All traces were 
fitted by a bi‑exponential equation and values of the kinetic rate constants were reported in Table 2. Inset describes the scheme of cTAR‑TAR anneal‑
ing
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monitored in real time (Fig. 6b, blue curve). The anneal-
ing reaction took more than 4000 s to form the final ED 
providing values of kobs1  =  5.3(±0.4)  ×  10−3  s−1 and 
kobs2 = 8.2(±0.8) × 10−4 s−1 (Table 1). When this experi-
ment was performed with 1 µM of TAR, the time to com-
plete the reaction was longer (8000 s) and both kobs1 and 
kobs2 were slower (Fig.  6c, blue curve and Table  2). For 
both cTAR-dTAR and cTAR-TAR systems, the kobs1,2 
values were about two to threefold higher with RPL7 as 
compared to Gag, indicating that RPL7 possesses a more 
potent nucleic acid annealing activity than Gag in the 
present conditions.
Finally, we investigated the chaperone activity of a Gag 
and RPL7 mixture. Interestingly, addition of 10  nM of 
Gag/RPL7 mixture (corresponding to 5  nM of Gag and 
5 nM of RPL7) induces a ~2.5-fold increase of the dou-
bly labelled cTAR fluorescence (Fig. 6a, panel III, dotted 
line), indicating that both proteins together can slightly 
destabilize the cTAR stem. Moreover, full annealing of 
cTAR with dTAR (Fig. 6b, green trace) or TAR (Fig. 6c, 
green trace) in presence of 100 nM of Gag/RPL7 mixture 
(corresponding to 50 nM of Gag and 50 nM of RPL7) was 
complete in less than 2000 and 4000  s, respectively for 
dTAR and TAR. Importantly, the kobs1,2 values with the 
Gag/RPL7 mixture is up to 1.5 to 3-fold higher than for 
the individual proteins in the case of the cTAR-dTAR sys-
tem and is up to 1.5 to 4-fold higher for the cTAR-TAR 
system (Tables 1, 2). The substantial increase in both the 
nucleic acid destabilization and annealing activity of the 
protein mixture as compared to each protein indicates 
that the two proteins act in concert to promote nucleic 
acid annealing. These data suggest that Gag can improve 
its nucleic acid chaperone activity through the concerted 
activity of RPL7.
Discussion
In HIV-1 infected cells, virus assembly is orchestrated 
by the structural polyprotein precursor Gag, but where 
and how assembly initially takes place is poorly under-
stood. The current view stipulates that Gag binds specific 
motifs in the 5′ UTR of the FL viral RNA, which in turn 
causes its dimerization. The dimeric RNA genome is then 
thought to act as a platform to recruit Gag molecules via 
their NC domain [4, 7].
In order to better understand the initial step of Gag 
assembly, we wanted to identify cellular co-factors inter-
acting with the NC domain of Gag. Among the possible 
candidates, RPL7 was shown to interact with both Gag 
and NCp7 [28]. Using yeast two hybrid and co-IP experi-
ments, we confirmed that RPL7 interacts with Gag and 
NCp7 (Fig.  1) and that RPL7 can be incorporated in 
infectious particles (Fig.  2), together with other riboso-
mal proteins [64, 65]. Also, RPL7a can be incorporated 
into the virus as part of the Staufen1 ribonucleoprotein 
complex [66]; but RPL7 and RPL7a are different proteins 
since they exhibit only limited homology. As reported 
in Figs. 3 and 5 the Gag–RPL7 interaction relies on the 
two zinc fingers of GagNC and on both the N- and the 
C-terminal regions of RPL7. Data also indicates that the 
interaction of Gag with RPL7 is marginally dependent 
on RNA (Fig.  3) as well as on Gag oligomerization and 
its interaction with the plasma membrane (Fig. 4). Taken 
together, formation of the Gag–RPL7 complex seems to 
rely on direct protein–protein interaction or involves 
a still unidentified factor independent from the RNA-
driven Gag assembly.
Noticeably, the amount of co-immunoprecipitated 
RPL7 with Gag was clearly increased upon RNase treat-
ment (Fig.  3c), suggesting that RNA could outcompete 
the Gag–RPL7 interaction. Since the NC domain of 
Gag, as well as the N- and C- termini of RPL7 interact 
with RNA [34, 35], this suggests an overlap between the 
GagNC-RPL7 interacting domains and nucleic acid bind-
ing domains. Further studies on the tripartite complex 
Gag–RPL7-RNA should clarify a potential role of RNA, 
either cellular or viral, to regulate Gag–RPL7 complex 
formation.
We also show that RPL7 promotes the annealing of 
the complementary cTAR to dTAR or to TAR sequences 
(Fig.  6b, c). This property for a ribosomal protein to 
exhibit nucleic acid chaperone activity has been pre-
viously reported for an E. coli protein [38, 39] but not 
for a mammalian ribosomal protein. This nucleic acid 
Table 1 Kinetic parameters for  the annealing of  cTAR 
to  dTAR in  the presence of  Gag, RPL7 and  the mixture 
of the two proteins
RPL7 Gag Gag + RPL7
a 0.58 ± 0.01 0.46 ± 0.01 0.80 ± 0.01
kobs1 (s
−1) (10.6 ± 0.8) × 10−3 (5.3 ± 0.4) × 10−3 (14 ± 0.7) × 10−3
kobs2 (s
−1) (10.2 ± 0.3) × 10−4 (8.2 ± 0.8) × 10−4 (18 ± 1) × 10−4
If/Io 6.5 ± 0.6 6.8 ± 0.5 7.2 ± 0.2
Table 2 Kinetic parameters for  the annealing of  cTAR 
to  TAR in  the presence of  Gag, RPL7 and  mixture of  two 
proteins
RPL7 Gag Gag + RPL7
a 0.41 ± 0.04 0.22 ± 0.028 0.67 ± 0.01
kobs1 (s
−1) (44 ± 1) × 10−4 (13.5 ± 0.7) × 10−4 (57 ± 1) × 10−4
kobs2 (s
−1) (39 ± 2) × 10−5 (20.5 ± 0.7) × 10−5 (47 ± 1) × 10−5
If/Io 8.2 ± 0.2 6.1 ± 0.2 8.45 ± 0.3
Page 10 of 14Mekdad et al. Retrovirology  (2016) 13:54 
chaperoning activity of RPL7 leads us to propose that 
RPL7 could facilitate structural rearrangements of 
mRNA during translation. Meanwhile, we confirmed that 
Gag has a weak nucleic acid chaperone activity especially 
for RNA (Fig. 6c) [22–24], and that both proteins can act 
in concert to promote nucleic acid destabilization and 
annealing.
Thus, collectively, our data show that Gag interacts 
with RPL7, a cellular protein endowed with chaperone 
activity (Fig. 7). In the infected cell, when the unspliced 
HIV-1 FL RNA is exported from the nucleus to the cyto-
plasm and there transported to the virion assembly site 
by diffusion [67, 68] or by the microtubule/dynein path-
way [69–72], it serves both as the gRNA and mRNA. As 
mRNA, it is recruited by the translational machinery to 
produce the Gag and GagPol polyproteins (Fig.  7—step 
1) and as the gRNA it is selected by newly made Gag/
GagPol. This latter specific interaction in turn causes its 
dimerization (Fig.  7—step 2) and tRNALys, 3 placement 
onto the genome (not shown in this scheme), concomit-
tant with assembly (Fig. 7—step 3). However, the nucleic 
acid chaperone activity of GagNC is low (this study and 
[22–24, 73]) favoring the notion that Gag could recruit 
a cellular partner to facilitate these RNA annealing reac-
tions. In line with this notion, the human RHA, also 
known as DHX9 was shown to participate in primer 
tRNALys, 3 annealing to the viral RNA [27]. Here, we go 
further proposing a model where Gag physically recruits 
RPL7 in an RNA independent manner to enhance its 
chaperone activity. Since the annealing activity of the 
Gag–RPL7 complex corresponds to the sum of the activi-
ties of the individual proteins (Fig.  6b, c, green curves), 
we propose that the complex might rapidly direct HIV-1 
FL RNAs dimerization and primer tRNA annealing at the 
start of Gag assembly (Fig.  7—step 3). In addition, Gag 
and RPL7 were shown to inhibit translation through an 
unknown mechanism [35, 37, 74–77], possibly causing a 
functional switch from RNA translation to Gag assembly. 
This hypothesis is presently under investigation.
Conclusion
Here we report that the cellular ribosomal protein RPL7 
appears to be a Gag helper chaperoning factor possibly 
acting in concert with the nucleic acid chaperone activ-
ity of GagNC during assembly. Further experiments are 
needed to elucidate the function of Gag–RPL7 on the 
translation of mRNA and the regulation of the balance 
between FL RNA translation and encapsidation.
Methods
Two‑hybrid system
Using the Gateway™ recombination technology (Life 
Technologies) a human RPL7 cDNA was cloned into 
pActII in fusion with the Gal4p Activation Domain 
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Fig. 7 Proposed model for Gag mediated recruitment of RPL7 during HIV replication. Part of the late phase of HIV‑1 replication is summarized in 
three steps, translation [1], dimerization of FL RNA [2] and its encapsidation [3]. Gag is in grey, the NC domain of Gag in red and RPL7 in blue
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(Gal4AD), Gag and NCp7 cDNA were cloned into 
pGBKT7 in fusion to the Gal4p DNA binding domain 
(Gal4BD). All pActII and pGBKT7 constructs were 
introduced into the S. Cerevisiae strain AH109 (MAT a, 
trp 1-901, leu2-3, 112, ura3-52, his3-200, Δgal4, Δgal80, 
LYS2: GAL1UAS-GAL1TATA-HIS3, GAL2UAS-GAL-
2TATA-ADE2, URA3: MEL1UAS-MEL1TATA-lacZ) or 
Y187 (MATα, ura3-52, his3-200, ade2-101, trp1-901, 
leu2-3, 112, gal4Δ, met–, gal80Δ, URA3::GAL1UAS-
GAL1TATA-lacZ) respectively using a LiCl procedure 
[78]. The transformed cells were selected for Leu or 
Trp auxotrophy on minimal media plates (6.8  g  L−1 
YNB w/o amino acids (Sigma ref Y0626), 0.6  g  L−1 of 
Drop OUT (ForMedium LTD, Hunstanton, England), 
2 % glucose, 20 g L−1 Bacto-agar (Difco ref 214010). To 
carry out the two-hybrid test, yeast cells of each mat-
ing type transformed with the studied constructs were 
mated overnight and the diploids selected on a mini-
mal medium depleted for Leu and Trp. The interaction 
between the two proteins tested was assayed by a 5-days 
growth of diploid yeasts on a minimal medium depleted 
for Leu, Trp and His.
Plasmid DNA
The human-codon-optimized Pr55Gag and pNL4-3EGFP 
encoding plasmids were kindly provided by David E. 
Ott (National Cancer Institute at Frederick, Maryland) 
and Barbara Muller (Department of Infectious Diseases, 
Heidelberg). Pr55Gag plasmid was used to obtain modi-
fied Gag proteins (Gag ΔZF1, GagΔZF2, GagΔZF1ΔZF2, 
GagRAPAAA and GagΔNC) by PCR-based site-directed 
mutagenesis following the supplier’s protocol as previ-
ously described (Thermo Scientific, F541) [79]. Construc-
tion of plasmids expressing Gag-eGFP and NCp7-eGFP 
were already described [79, 80]. The 3X Flag RPL7 was 
obtained by cloning the RPL7 (NCBI ref NM_000971.3) 
cDNA in frame with three copies of the Flag tag (DYK-
DDDDK) into a pCI-neo (Promega) backbone using the 
Gateway™ recombination technology (Life technologies). 
The integrity of all plasmid constructs was assessed by 
DNA sequencing (GATC Biotech, Germany).
Cell culture and plasmid transfection
2 × 105 HeLa cells (from ATCC, CCL-2 Amp, HeLa; Cer-
vical Adenocarcinoma; Human) were cultured in 6-wells 
plate containing Dulbecco’s modified Eagle medium sup-
plemented with 10 % fetal bovine serum (Invitrogen Cor-
poration, Cergy Pontoise, France) and 1 % of an antibiotic 
mixture (penicillin/streptomycin DE17-602E: Lonza, Bal, 
Switzerland, DE16-602E) at 37  °C in a 5  % CO2 atmos-
phere. HeLa cells were transfected or co-transfected 
using jet PEI™ (Life Technologies, Saint Aubin, France).
HIV purification and cell infection
CEM-SS cells [81] were infected with HIV-1 LAI. After 
3 days of culture, the cells were splited into two batches 
to analyze the percentage of infected cells by intracellu-
lar p24 staining, using anti-HIV-1 core protein p24 (Ref 
RD-1, Beckman Coulter), and to measure the expression 
of p24 and RPL7 by flow cytometry and by western blot 
[40, 82].
To analyze the presence of RPL7, HIV-1 strain BaL 
primary isolate (subtype B, HIV-1 R5 strain, provided 
through the AIDS Research and Reference Reagent 
Program from Dr. S. Gartner; Department of Neurol-
ogy, Johns Hopkins Hospital, Baltimore, MD, and Drs. 
M. Popovic and R. Gallo, Institute of Human Virology, 
University of Maryland Biotechnology Institute and 
Department of Microbiology, Baltimore, MD) was pro-
duced on PHA-activated peripheral blood mononuclear 
cell (PBMC). The virus stock was purified from cul-
tured supernatant by a gel-filtration exclusion method 
on Sephacryl S-1000 Superfine (Amersham) columns 
as described previously [41, 82]. Supernatant of mock-
infected cells was purified in parallel. The purified frac-
tions were concentrated by 80-fold through a 100  kDa 
cut-off polyethersulfone filter (Centricon 80 Plus Biomax 
Filter; Millipore, Molsheim, France) before analysis by 
western blot.
Immunoprecipitation and western blotting
HeLa cells were transfected and 24  h post-transfection, 
cells were harvested after trypsin treatment and resus-
pended in lysis buffer (10 mM Tris/HCl pH 7.5, 150 mM 
NaCl, 1 mM EDTA, 1 % NP40, 0.5 % SDS) supplemented 
with complete protease inhibitor cocktail (Roche Diag-
nostics GmbH). Cell lysates were cleared by centrifu-
gation, and the supernatant corresponding to 1  mg of 
protein was incubated with primary antibody either 
mouse anti-p24 (Ref 6521 #24-4; AIDS Reagent Pro-
gram, Division of AIDS, NIAID, NIH from Dr. Michael 
H. Malim), mouse anti-Flag (Sigma, F1804), or mouse 
anti-eGFP (Lifetech, A11120) for 2 h at 4 °C under con-
tinuous agitation. Protein A magnetic beads (Millipore, 
Pure Proteome, LSKMAGA10) were added for 90 min at 
4 °C, and washed twice with ice-cold lysis buffer. Immu-
noprecipitated proteins (IP and Co-IP) and cell lysates 
(input) were analyzed by 10  % SDS-PAGE and mem-
branes blotted either by mouse anti-p24 (Ref 6521 #24-
4; AIDS Reagent Program, Division of AIDS, NIAID, 
NIH from Dr. Michael H. Malim), rabbit anti-Flag 
(Sigma, F1804), mouse anti-eGFP (Proteintech 66002-
1), mouse anti-GAPDH (Millipore,MAB374) or rabbit 
anti-RPL7 (Abcam, ab72550) antibodies followed by anti-
mouse HRP conjugate (Promega, W4021, 1:10,000) or 
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anti-rabbit HRP (Promega, W401B) or by Protein A HRP 
(horseradish peroxidase, invitrogen, 10-1023).
For RNAse assay, the supernatant containing 1  mg of 
protein was incubated with a mixture containing 5 unit 
of RNAse A and 200 units of RNAse T1 (AM 2286) for 30 
mn at room temperature. To verify RNAse activity, RNAs 
were extracted by addition of phenol–chloroform (v/v) 
using the kit “Tri Reagent Protocol” from sigma Aldrich 
(T9424). After extensive vortex and centrifuge at 12,000g, 
the supernatant was mixed with RNA loading dye (New 
England Biolabs, B0363S), loaded on a TAE (Tris Acetate 
EDTA) 1× 1  % agarose gel and visualized by Ethidium 
Bromide. Ladder was supplied from New England Bio-
labs (N3232S) (Additional file 1: Fig. S1).
Protein purification
BL21 (DE3) cells were cultured in LB (Luria–Bertani) 
medium (1 % (w/v) peptone, 0.5 % (w/v) yeast extract, and 
0.5 % NaCl). The medium was supplemented with kana-
mycin (50 µg mL−1) and chloramphenicol (25 µg mL−1) in 
order to purify HIV-1 Gag, and kanamycin (50 µg mL−1) 
and ampicillin (50  µg  mL−1) to purify human RPL7. 
Recombinant protein production was performed by 
inoculating a single colony in 50 mL LB containing anti-
biotics, and cultured at 37 °C, overnight with shaking at 
220 rpm. The overnight culture was used to inoculate 1 
L LB containing antibiotics. The culture was grown at 
37 °C, 220 rpm, until an absorbance at 600 nm of 0.6 was 
reached. Protein expression was induced by addition of 
1  mM IPTG (Isopropyl β-d-1-thiogalactopyranoside) 
for 3 h at 37 °C or of 0.5 mM IPTG for 16 h at 18 °C for 
RPL7 or Gag, respectively. Bacteria were harvested and 
snap frozen in liquid nitrogen and stored at −80  °C. 
Both proteins were purified using previously described 
protocols [83, 84] and their purity was checked by poly-
acrylamide gel electrophoresis (Additional file 2: Fig. S2). 
Their concentration was measured from their absorb-
ance at 280 nm using εRPL7 = 27,000 L mol−1 cm−1 and 
εGag = 63,000 L mol−1 cm−1.
Monitoring nucleic acid annealing kinetics by fluorescence 
spectroscopy
Kinetic measurements were performed in pseudo first-
order conditions by using 10  nM of cTAR labeled at 
its 5′ and 3′ ends by 6-carboxyrhodamine (Rh6G) and 
4-(4′-dimethylaminophenylazo)benzoic acid (Dab-
cyl) with a 100  nM concentration of unlabeled dTAR 
(or 1 µM of TAR) as previously described [19, 85]. The 
reaction was monitored by recording the changes in 
the Rh6G fluorescence intensity at 555  nm (with exci-
tation at 520  nm) with time. Proteins (Gag or RPL7) 
were added at a 1 molar ratio to each reactant sepa-
rately and then, the reaction was initiated by mixing the 
protein-coated oligonucleotides together. The apparent 
rate constants kobs and the amplitudes (a) were deter-
mined from the kinetic traces by including a dead-time 
correction t0 to take into account the delay between 
mixing the reactants and the start of the measurements. 
All fitting procedures were carried out with Origin™ 8.6 
software based on nonlinear, least-square methods and 
the Levenberg–Marquardt algorithm. Emission spec-
tra and kinetic traces were recorded with Fluorolog 
and FluroMax spectrofluorimeters (Jobin–Yvon 
Instruments, S.A. Inc.) equipped with a temperature-
controlled cell compartment locked at 20  °C. All fluo-
rescence intensities were corrected for buffer emission 
and lamp fluctuations. Experiments were performed 
at 20  °C in 50 mM Hepes, 150 mM NaCl, 1 mM DTT, 
1 mM MgCl2, pH 7.4.
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